Sarcoma  >>  dasatinib  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dasatinib / Generic mfg.
NCT00734864: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

Withdrawn
1
0
US
enzyme-inducing anti-epileptic drugs
Annick Desjardins, Bristol-Myers Squibb
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
06/10
06/12
NCT00609999: Ph I Dasatinib + Erlotinib in Recurrent MG

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Completed
1
47
US
Erlotinib and Dasatinib, Dasatinib, Erlotinib, Tarceva, Sprycel
Duke University, Bristol-Myers Squibb, Genentech, Inc.
Glioblastoma, Gliosarcoma
07/10
07/10
NCT01643278: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Completed
1
29
US
Dasatinib, BMS-354825, Sprycel, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma
06/16
06/16
NCT01916135: PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Completed
1
11
US
[18F]-SKI-249380, PET/CT scan, Blood draws
Memorial Sloan Kettering Cancer Center
Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
04/20
04/20

Download Options